Company intelligence / Profile preview
Neurimmune
Zurich-Schlieren, Switzerlandneurimmune.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 3
01
Overview
Neurimmune has advanced multiple antibody programs into clinical development, including ALXN2220/NI006 for ATTR cardiomyopathy, which is in Phase 3 and has received FDA Fast Track designation. Aducanumab, developed with Biogen for Alzheimer’s disease, reached commercial stage. Other programs are at various stages from preclinical to early clinical trials[2][5].
- Therapeutic areas
- EndocrinologyCardiovascularNeurology
- Modalities
- Monoclonal antibodySmall moleculeGene therapy (vectorized human antibodies)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
BiogenAstraZeneca/Alexion PharmaceuticalsOno PharmaceuticalEli Lilly Chorus unitTVM Capital
Beyond the preview
Go deeper on Neurimmune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurimmune.